Targeting Colon Cancer Cell NF-κB Promotes an Anti-tumour M1-like Macrophage Phenotype and Inhibits Peritoneal Metastasis
Overview
Authors
Affiliations
In a model of peritoneal metastasis in immune-competent mice, we show that nuclear factor (NF)-κB inhibition in CT26 colon cancer cells prevents metastasis. NF-κB inhibition, by stable overexpression of IκB-α super-repressor, induced differential polarization of co-cultured macrophages to an M1-like anti-tumour phenotype in vitro. NF-κB-deficient cancer cell-conditioned media (CT26/IκB-α SR) induced interleukin (IL)-12 and nitric oxide (NO) synthase (inducible NO synthase (iNOS)) expression in macrophages. Control cell (CT26/EV) conditioned media induced high levels of IL-10 and arginase in macrophages. In vivo, this effect translated to reduction in metastasis in mice injected with CT26/ IκB-α SR cells and was positively associated with increased CD8(+)CD44(+)CD62L(-) and CD4(+)CD44(+)CD62L(-) effector T cells. Furthermore, inhibition of NF-κB activity induced high levels of NO in infiltrating immune cells and decreases in matrix metalloproteinase-9 expression, simultaneous with increases in tissue inhibitor of metalloproteinases 1 and 2 within tumours. CT26/IκB-α SR tumours displayed increased pro-inflammatory gene expression, low levels of angiogenesis and extensive intratumoral apoptosis, consistent with the presence of an anti-tumour macrophage phenotype. Macrophage depletion reduced tumour size in CT26/EV-injected animals and increased tumour size in CT26/IκB-α SR cells compared with untreated tumours. Our data demonstrate, for the first time, that an important implication of targeting tumour cell NF-κB is skewing of macrophage polarization to an anti-tumour phenotype. This knowledge offers novel therapeutic opportunities for anticancer treatment.
NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.
Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.
PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.
NF-κB signaling pathway in tumor microenvironment.
Cao Y, Yi Y, Han C, Shi B Front Immunol. 2024; 15:1476030.
PMID: 39493763 PMC: 11530992. DOI: 10.3389/fimmu.2024.1476030.
NF-κB downstream miR-1262 disturbs colon cancer cell malignant behaviors by targeting FGFR1.
Zhang W, Huang Z, Xiao Z, Wang H, Liao Q, Deng Z Acta Biochim Biophys Sin (Shanghai). 2023; 55(11):1819-1832.
PMID: 37867436 PMC: 10686795. DOI: 10.3724/abbs.2023235.
Bunsick D, Matsukubo J, Szewczuk M Cancers (Basel). 2023; 15(4).
PMID: 36831374 PMC: 9954791. DOI: 10.3390/cancers15041030.
Chen X, Deng Q, Li X, Xian L, Xian D, Zhong J Clin Cosmet Investig Dermatol. 2023; 16:407-417.
PMID: 36817639 PMC: 9936880. DOI: 10.2147/CCID.S396173.